SC
SLDB icon

Stempoint Capital’s Solid Biosciences SLDB Stock Holding History

Stempoint Capital’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.58M Buy
358,780
+163,377
+84% +$1.24M 0.62% 49
2026
Q1 		$1.41M Buy
+195,403
New +$1.26M 0.27% 60
2025
Q2 		– Sell
-198,150
Closed -$733K – 76
2025
Q1 		$733K Buy
+198,150
New +$848K 0.23% 48

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Stempoint Capital's SLDB Position: Q2 2026 in Review

Stempoint Capital increased its Solid Biosciences (SLDB) stake by 84% in Q2 2026, buying an estimated $1.24M and bringing the position to 358,780 shares worth $3.58M. The position accounts for 0.62% of the portfolio, ranked #49.

Stempoint Capital first reported a position in SLDB in Q1 2025 and has held it in 3 quarters since. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

  • Stempoint Capital held 358,780 shares of Solid Biosciences worth $3.58M as of Q2 2026.
  • Stempoint Capital bought 163,377 Solid Biosciences shares in Q2 2026, an estimated $1.24M.
  • Solid Biosciences made up 0.62% of Stempoint Capital's portfolio in Q2 2026, its #49 holding.
  • Stempoint Capital first reported a position in Solid Biosciences in Q1 2025 and has held it in 3 quarters since.
  • 157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.